Oppenheimer Asset Management Inc. Purchases New Shares in IDEAYA Biosciences, Inc. $IDYA

Oppenheimer Asset Management Inc. acquired a new stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) in the second quarter, Holdings Channel reports. The institutional investor acquired 14,847 shares of the company’s stock, valued at approximately $553,000.

A number of other large investors have also modified their holdings of IDYA. Farther Finance Advisors LLC boosted its stake in shares of IDEAYA Biosciences by 171.1% during the 4th quarter. Farther Finance Advisors LLC now owns 919 shares of the company’s stock worth $32,000 after acquiring an additional 580 shares in the last quarter. ANTIPODES PARTNERS Ltd grew its position in shares of IDEAYA Biosciences by 49.4% during the 4th quarter. ANTIPODES PARTNERS Ltd now owns 1,150 shares of the company’s stock valued at $40,000 after acquiring an additional 380 shares during the period. Global Retirement Partners LLC purchased a new position in shares of IDEAYA Biosciences in the 4th quarter valued at about $61,000. Daiwa Securities Group Inc. raised its holdings in IDEAYA Biosciences by 16.1% in the 2nd quarter. Daiwa Securities Group Inc. now owns 3,141 shares of the company’s stock worth $66,000 after purchasing an additional 436 shares during the period. Finally, Fifth Third Bancorp acquired a new position in IDEAYA Biosciences in the 1st quarter worth about $84,000. Institutional investors and hedge funds own 98.29% of the company’s stock.

Insider Activity

In other news, CAO Briseno Andres Ruiz sold 9,550 shares of the company’s stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $40.01, for a total value of $382,095.50. Following the completion of the sale, the chief accounting officer directly owned 26,466 shares in the company, valued at $1,058,904.66. This represents a 26.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 4.70% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on IDYA shares. Truist Financial lowered their price target on IDEAYA Biosciences from $63.00 to $59.00 and set a “buy” rating on the stock in a research report on Wednesday, August 5th. Cantor Fitzgerald restated an “overweight” rating on shares of IDEAYA Biosciences in a research report on Friday, May 22nd. Wedbush upped their target price on IDEAYA Biosciences from $58.00 to $60.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 5th. Wall Street Zen lowered IDEAYA Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday. Finally, Citigroup reissued a “market outperform” rating on shares of IDEAYA Biosciences in a research note on Tuesday, June 2nd. Fourteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $50.12.

IDEAYA Biosciences Trading Up 0.7%

NASDAQ:IDYA opened at $36.54 on Tuesday. The company has a market cap of $3.21 billion, a P/E ratio of -18.84 and a beta of -0.10. IDEAYA Biosciences, Inc. has a twelve month low of $23.23 and a twelve month high of $40.58. The company’s 50-day moving average price is $35.30 and its 200-day moving average price is $32.71.

IDEAYA Biosciences (NASDAQ:IDYA) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($1.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.06) by ($0.16). The business had revenue of $8.86 million for the quarter, compared to analysts’ expectations of $8.02 million. IDEAYA Biosciences had a negative net margin of 75.93% and a negative return on equity of 16.73%. The firm’s revenue was up 8800.0% on a year-over-year basis. During the same period in the prior year, the company posted ($0.88) EPS. On average, analysts expect that IDEAYA Biosciences, Inc. will post -4.38 earnings per share for the current year.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.